Arkolith/Insider Trading/RNXT/Form 4

Gentry Leesa

Chief Clinical OfficerRenovoRx, Inc. (RNXT) · full profile →Form 4 · filed Mar 8, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 6, 2024Grant(A)190K——190K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-24-009409) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML